Boston Scientific's Lotus Valve system is a transcatheter aortic valve that allows physicians to reposition and retrieve it before placement. Lotus earned CE Mark in October 2013 but is being studied in the REPRISE III pivotal trial in the United States.

Boston Scientific executives recently reported strong results in its Structural Heart division, naming Lotus as a significant contributor to that strength. At the company's recent investor day meeting, executives forecasted a U.S. launch of Lotus by the end of 2017.